Background: Human herpesvirus 6 (HHV-6) encephalitis is a known life-threatening
| INTRODUC TI ON
Human herpes virus 6 (HHV-6), which includes HHV-6A and HHV-6B, belongs to Roseolaviruses, although HHV-6A and HHV-6B are today considered as two different species. HHV-6B causes exanthema subitum and is mostly reactivated after allogeneic hematopoietic stem cell transplantation (allo-HSCT). HHV-6 reactivation occurs in approximately 50% of allo-HSCT recipients 1,2 and often occurs 0-9 days after neutrophil engraftment. The peak viral load is observed approximately 3-4 weeks after allo-HSCT. 1, 2 HHV-6 can cause skin rash, interstitial pneumonia, encephalitis, and myelosuppression, among other conditions. [3] [4] [5] [6] [7] Particularly, encephalitis caused by HHV-6 can be fatal. HHV-6 encephalitis typically develops during the early engraftment period at approximately 18-24 days after allo-HSCT. 1, [8] [9] [10] HHV-6 encephalitis starts with damage to the cerebral limbic system including the hippocampus, followed by the development of symptoms that typically include disturbed consciousness, impaired short-term memory, and seizures.
HHV-6 encephalitis is reported more frequently in cases of cord blood transplantation (CBT) than in cases of non-CBT, ie, bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT). 8, [11] [12] [13] [14] [15] [16] Mycophenolate mofetil (MMF) is an immunosuppressive drug used as prophylaxis for graft-versus-host disease (GVHD). Viral infection develops more frequently in patients who have received MMF than in those who have received short-term methotrexate (MTX). 17 The incidence of HHV-6 encephalitis in patients receiving MMF is unclear. This study aimed to investigate the impact of MMF administered for GVHD prophylaxis in the occurrence of HHV-6 encephalitis after allo-HSCT and the characteristics of this condition.
| PATIENTS AND ME THODS
This retrospective study was conducted at Kobe University Hospital and included patients who met the following inclusion criteria: (a) age ≥18 years; (b) presence of a hematological disease; (c) adminis- primers and probe setting were previously described. 19, 20 Brain magnetic resonance imaging (MRI) was performed to rule out posterior reversible encephalopathy syndrome.
This study was approved by the ethics committees of Kobe University and was conducted in accordance with the Declaration of Helsinki.
| Statistical analysis
Clinical data consisted of age at transplantation, sex, primary disease, disease status, stem cell source, human leukocyte antigen (HLA) mismatch, conditioning regimens, transfused cell count, laboratory findings, course of transplantation therapy, and outcomes.
We compared categorical and continuous variables using the
Fisher's exact test and the Mann-Whitney U-test, respectively.
Cumulative incidence curves were used in competing risks setting, with death treated as a competing event, to calculate the probability of HHV-6 encephalitis. All statistical tests were two-sided, and the AA, aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATL, adult T-cell leukemia/lymphoma; BMT, bone marrow transplantation; BU, busulfan; CBT, cord blood transplantation; CML, chronic myelogenous leukemia; CY, cyclophosphamide; CyA, ciclosporin; Flu, fludarabine; GVHD, graft versus host disease; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; Mel, melphalan; ML, malignant lymphoma; MMF, mycophenolate mofetil; MPD, myeloproliferative disorder; PBSCT, peripheral blood stem cell transplantation; RIC, reduced intensity conditioning; TAC, tacrolimus; TBI, total body irradiation.
TA B L E 1 Patient characteristics
against HHV-6 was not provided in any case. Only one patient (case 5), who presented with late onset HHV-6 infection 98 days after transplantation, had received ganciclovir (GCV) and foscarnet (FCN) for cytomegalovirus reactivation prior to the onset of HHV-6 encephalitis.
| Incidence of HHV-6 encephalitis
Seven patients developed HHV-6 encephalitis. The overall cumulative incidence of HHV-6 encephalitis at 100 days after transplantation was 8.4% (95% CI: 3.7%-15.7%; Figure 2A ). The cumulative incidences of HHV-6 encephalitis in patients who had undergone CBT and non-CBT were 12.1% (4/33 cases, 95% CI: 3.7%-25.8%) and 6% (3/50 cases, 95% CI: 1.5%-15%), respectively (P = 0.344, Figure 2B ). where TAC was administered for GVHD prophylaxis, the cumulative incidence of HHV-6 encephalitis was not significantly different between those who underwent CBT and non-CBT (18.2% vs 16.7%, P = 0.974; Figure 2C ). received the CY/TBI regimen, the cumulative incidence of HHV-6 encephalitis was 14.7% (5/34), which was higher than the overall cumulative incidence. The median onset of HHV-6 encephalitis was 23 days (range, 17-98 days) after allo-HSCT, which was just after neutrophil engraftment. A total of three of the seven patients had received steroid treatment for engraftment syndrome.
| Laboratory imaging findings
At the onset of HHV-6 encephalitis, the median CSF protein level was 50 mg/dL (range, 30-384 mg/dL), which was normal or moderately elevated, while the median CSF cell count was 5/mm 3 (range, 1-75/mm 3 ), which was normal or modestly elevated. The HHV-6 viral loads in CSF varied from case to case, but no significant differences were noted between BMT cases and CBT cases ( Table 2) 
| Neurological symptoms
The neurological symptoms associated with HHV-6 encephalitis, including convulsions and disturbed consciousness, were more severe in patients who had undergone BMT than those in patients who had undergone CBT. All three patients who developed HHV-6 encephalitis after BMT needed treatment with sedative agents and ventilators to manage convulsive seizures. By contrast, most patients who had undergone CBT and developed HHV-6 encephalitis could perform activities of daily living because the most common symptoms were only disturbed consciousness and short-term memory loss.
F I G U R E 2 Cumulative incidence of HHV-6 encephalitis. The overall cumulative incidence was 8.4% (A), and the incidence was not significantly different between the CBT cases and non-CBT (BMT and PBSCT) cases (B)
TA B L E 2 Cases of HHV-6 encephalitis ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; CB, cord blood; CR1, first complete remission; CR2, second complete remission; DOC, disturbance of consciousness; FCN, foscarnet; GCV, ganciclovir; HSCT, hematopoietic stem cell transplantation; M, male; MAC, myeloablative conditioning; MMF, mycophenolate mofetil; RIC, reduced-intensity conditioning; TAC, tacrolimus; TNC, total nucleated cell.
Two cases (cases 2 and 3) developed an autonomic storm, an excruciating autonomic dysfunction marked by a catecholamine surge, due to HHV-6-induced brain impairment, which made provision of general care difficult. Both patients had undergone BMT. Case 3 suddenly developed urinary retention 18 days after BMT. Concurrently, the patient experienced progression of disorientation, disturbed consciousness, and convulsion within a few hours of the onset of urinary retention. FCN was administered on the same day that we suspected HHV-6 encephalitis.
Immediately after he was transferred to the intensive care unit for the management of convulsion, the patient's blood pressure increased, and hyperhidrosis also developed, which led to hypothermia (minimum body temperature, 31°C). In addition, the patient had experienced persistent diarrhea (≥10 times a day) due to regimen-related toxicity until the previous day, but the diarrhea suddenly stopped. Although urinary retention and constipation can also occur owing to cauda equina syndrome or spinal cord disorder, we thought that his symptoms were caused by central autonomic disturbance because his neurological symptoms, such as hyperhidrosis, did not coincide with the spinal dermatome. Although status epilepticus stopped after 2 days, disturbed consciousness, hypertension, hyperhidrosis, and failure of thermoregulation persisted for up to 3 months. Case 2 also developed disturbed consciousness, status epilepticus and severe autonomic symptoms, including hypertension, constipation, abnormal sweating, and thermoregulation failure due to HHV-6 encephalitis. He required long-term ventilator therapy, and his autonomic symptoms persisted for up to 1 year.
F I G U R E 3
Changes in HHV-6 viral loads. Viral loads had decreased rapidly after antiviral treatment in all seven cases. FCN, foscarnet; GCV, ganciclovir
| Treatment
All seven patients with HHV-6 encephalitis were treated with an antiviral drug (FCN or GCV). The median duration of antiviral therapy was 39 days (range, 14-68 days). After antiviral therapy, HHV-6 DNA in CSF was no longer detectable in all seven cases (Figure 3 ).
The median time to reach undetectable levels of viral DNA in the CSF was 24 days (range 10-33). Although no patient experienced exacerbation or HHV-6 encephalitis-related mortality, one case (case 3) died due to HHV-6-related pneumonia after recovering from HHV-6 encephalitis. The majority of patients recovered from their symptoms without severe sequelae and returned to normal daily living, but patients who developed severe autonomic dysfunction developed neurological sequelae, such as disturbed consciousness and abnormal thermoregulation.
| D ISCUSS I ON
We retrospectively analyzed patients diagnosed with HHV-6 encephalitis after allo-HSCT who had been treated with the combination of a calcineurin inhibitor and MMF for GVHD prophylaxis in our hospital to assess the characteristics of HHV-6 encephalitis in patients receiving MMF for GVHD prophylaxis after allo-HSCT.
The reported incidence of HHV-6 encephalitis after allo-HSCT range from 0.95% 22 to 11.6%. 23 This variability in HHV-6 incidence may be a result of the varying transplantation methods (eg, conditioning regimens, stem cell sources, and GVHD prophylaxis). In a systematic review conducted by Scheurer, the overall incidence of HHV-6 encephalitis in CBT and non-CBT patients was 8.3% and 0.5%, respectively. 14 In a study focused on the incidence of HHV-6 encephalitis confirmed via polymerase chain reaction testing of CSF in Japan, the overall incidence were 3%-6.5%, 15,24 4.9%-15.4%, 24 and 0.7%-3.0% 11, 24 in all cases, CBT cases, and non-CBT cases, respectively. The recent report from Japan which was a large-scale retrospective analysis revealed that the cumulative incidences of HHV-6 encephalitis 100 days after transplantation in all cases, BMT or PBSCT and CBT cases were 2.3%, 1.6%, and 5.0%, respectively.
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The incidence rates in our cohort tend to be higher than those in previous reports. Given that short-term methotrexate as replacement for MMF has been widely used for allo-HSCT patients in Japan, our study suggests that MMF could increase the risk of HHV-6 encephalitis in both BMT patients and CBT patients. This may be due to the strong immunosuppression that is a result of long-term exposure of lymphocytes to MMF. Recently, Miyashita et al also suggested that MMF is a risk factor for HHV-6 encephalitis. 16 However, all patients with HHV-6 encephalitis/myelitis who had received MMF for GVHD prophylaxis in that report had undergone CBT. 16 Their non-CBT patients who had HHV-6 encephalitis/myelitis had not received MMF. In our study, we found that HHV-6 encephalitis with severe clinical courses occurred in cases of BMT receiving MMF. Our study is the first to suggest the possibility that MMF increases the incidence of severe HHV-6 encephalitis in non-CBT patients, particularly BMT patients.
Previous studies reported other risk factors for HHV-6 encephalitis aside from CBT, including engraftment syndrome 26 and acute GVHD. 13, 26 Male sex is also reported as a risk factor for HHV-6 reactivation, 15 and notably, patients with HHV-6 encephalitis in our cohort were all male. 
29
Our study has certain limitations, with the small number of cases included being the major limitation. More data need to be collected to validate our findings. In addition, standard diagnostic criteria for HHV-6 encephalitis are not established, and various clinical examinations were performed to diagnose encephalitis across studies.
Hence, we could not compare our findings with that of previous studies. Additionally, if encephalitis is not suspected, the routine CSF examinations after allo-HSCT are not performed, and thus mild encephalitis may be missed.
In conclusion, the results of this retrospective study indicate that the combination of a calcineurin inhibitor and MMF for GVHD prophylaxis might increase the risk of severe HHV-6 encephalitis in cases of non-CBT, particularly BMT. Although GCV and FCN are effective against HHV-6 and lead to better survival, MMF should be administered with caution, and patients should be monitored closely for HHV-6 encephalitis, even in those who underwent non-CBT. Further investigations should be conducted to validate our findings.
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